Trade and Medical Media Only Taiho Oncology Europe GmbH announced today the UK launch of Lytgobi® (futibatinib), an irreversibly binding fibroblast growth factor receptor (FGFR) inhibitor.1,3 This ...
Zurich, Switzerland, December 03, 2025 - MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive ...
12 小时
MUVON Therapeutics Reports Positive Phase 2 Results for its First-in-Class Muscle Precursor ...
MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive topline results from the Phase 2 clinical trial SUISSE-MPC2 (NCT05534269)evaluating its novel proprietary muscle ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈